Seoul: Stocks rise 1% on virus treatment hopes, drop in new cases
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[SEOUL] South Korean shares rose just over 1 per cent on Monday, in line with Asian peers, as the US drug regulator's authorisation of the use of blood plasma from recovered patients as a Covid-19 treatment lifted sentiment, while new domestic cases slowed.
The benchmark Kospi closed up 25.24 points, or 1.10 per cent, to 2,329.83.
The sub-index for pharmaceutical sector jumped 2.9 per cent, following the authorisation from the US Food & Drug Administration on Sunday.
South Korea reported 266 new infections on Monday, down from 397 on Sunday, bringing the national tally to 17,655 with 309 deaths.
South Korea's central bank chief said the bank would maintain its accommodative monetary policy as a recent surge in infections will likely weaken the country's economic recovery. The bank will hold its monetary policy meeting on Thursday.
Foreigners were net buyers of US$166.97 million worth of shares on the main board.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
